Log in
NASDAQ:VYNE

VYNE Therapeutics Stock Forecast, Price & News

$1.82
-0.12 (-6.19 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.80
Now: $1.82▼
$1.93
50-Day Range
$1.35
MA: $1.72▼
$1.97
52-Week Range
$1.00
Now: $1.82▼
$7.48
Volume1.46 million shs
Average Volume2.41 million shs
Market Capitalization$305.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.25 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYNE
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.menlotherapeutics.com
Phone800-775-7936
Employees40

Debt

Debt-to-Equity Ratio0.46
Current Ratio4.92
Quick Ratio4.68

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.64 million
Price / Sales28.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.81 per share
Price / Book0.65

Profitability

EPS (Most Recent Fiscal Year)($3.09)
Net Income$-73,700,000.00
Net MarginsN/A
Return on Equity-331.83%
Return on Assets-210.68%

Miscellaneous

Outstanding Shares167,690,000
Market Cap$305.20 million
Next Earnings Date10/29/2020 (Estimated)
OptionableNot Optionable
$1.82
-0.12 (-6.19 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VYNE Therapeutics (NASDAQ:VYNE) Frequently Asked Questions

How has VYNE Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

VYNE Therapeutics' stock was trading at $3.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VYNE shares have decreased by 44.8% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of VYNE Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VYNE Therapeutics.

When is VYNE Therapeutics' next earnings date?

VYNE Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for VYNE Therapeutics.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $1.00. The firm had revenue of $11.69 million for the quarter, compared to analyst estimates of $2.04 million.
View VYNE Therapeutics' earnings history.

What price target have analysts set for VYNE?

6 brokerages have issued twelve-month price targets for VYNE Therapeutics' shares. Their forecasts range from $3.00 to $8.00. On average, they expect VYNE Therapeutics' share price to reach $5.50 in the next twelve months. This suggests a possible upside of 202.2% from the stock's current price.
View analysts' price targets for VYNE Therapeutics.

Who are some of VYNE Therapeutics' key competitors?

Some companies that are related to VYNE Therapeutics include Arcturus Therapeutics (ARCT), Ligand Pharmaceuticals (LGND), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), Endo International (ENDP), Mersana Therapeutics (MRSN), MacroGenics (MGNX), Kiniksa Pharmaceuticals (KNSA), Theravance Biopharma (TBPH), NGM Biopharmaceuticals (NGM), Zogenix (ZGNX), Karyopharm Therapeutics (KPTI), Nabriva Therapeutics (NBRV), Cytokinetics (CYTK) and Applied Molecular Transport (AMTI).
View all competitors.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), OrganiGram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), BioNano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

Who are VYNE Therapeutics' key executives?

VYNE Therapeutics' management team includes the following people:
  • Mr. David T. Domzalski, CEO, Pres & Director (Age 53, Pay $891k)
  • Ms. Mutya Harsch, Gen. Counsel, Chief Legal Officer & Company Sec. (Age 45, Pay $556k)
  • Dr. Darrell S. Rigel M.S., M.D., MS, Consultant (Age 70, Pay $40.2k)
  • Mr. Andrew Saik, CFO & Treasurer (Age 51)
  • Dr. Iain A. Stuart, Chief Scientific Officer (Age 47)
  • Mr. Raymond G. Steitz, Sr. VP of Global HR (Age 61)
  • Dr. Russell Elliott, Sr. VP of Pharmaceutical Devel. (Age 54)
  • Mr. Matthew Wiley, Chief Commercial Officer (Age 48)

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Regentatlantic Capital LLC (0.01%). Company insiders that own VYNE Therapeutics stock include Andrew Saik, David Domzalski and Perceptive Advisors Llc.
View institutional ownership trends for VYNE Therapeutics.

Which institutional investors are buying VYNE Therapeutics stock?

VYNE stock was bought by a variety of institutional investors in the last quarter, including Regentatlantic Capital LLC. Company insiders that have bought VYNE Therapeutics stock in the last two years include Andrew Saik, David Domzalski, and Perceptive Advisors Llc.
View insider buying and selling activity for VYNE Therapeutics.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VYNE Therapeutics' stock price today?

One share of VYNE stock can currently be purchased for approximately $1.82.

How big of a company is VYNE Therapeutics?

VYNE Therapeutics has a market capitalization of $305.20 million and generates $10.64 million in revenue each year. The company earns $-73,700,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis. VYNE Therapeutics employs 40 workers across the globe.

What is VYNE Therapeutics' official website?

The official website for VYNE Therapeutics is www.menlotherapeutics.com.

How can I contact VYNE Therapeutics?

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company can be reached via phone at 800-775-7936 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.